Expression and function analysis of CRABP2 and FABP5, and their ratio in esophageal squamous cell carcinoma

Abstract Objective The purpose of this study was to explore the effect of CRABP2 and FABP5, and their ratio on prognosis in esophageal squamous cell carcinoma. Methods The expression data of CRABP2 in esophageal cancer in TCGA and GEO were collected by the public database GEPIA. The expression levels of CRABP2 and FABP5 were examined using immunohistochemistry. The relationship between the two proteins and related clinicopathological parameters were analyzed by χ 2 test. Survival analysis was used to investigate the effect of CRABP2 and FABP5, and their ratio on prognosis. Results Compared with normal esophageal mucosal epithelium, there was lower CRABP2 gene mRNA in the esophageal cancer tissue, and the difference was statistically significant (p < 0.01). For the expression level, no significant difference was observed in patients with stages I–IV in esophageal cancer. Immunohistochemistry showed that CRABP2 and FABP5 were both highly expressed in normal esophageal squamous epithelial cells at 100 and 94.1%, while lower in ESCC (75.6 and 58.7%). There was a significant difference in the expression between cancer and adjacent tissues (p < 0.001). No inherent relationship was manifested between the CRABP2 expression and the clinical parameters of the ESCC. The expression of FABP5 was related to lymph node metastasis (p = 0.032), the depth of invasion (p = 0.041), and the AJCC stage (p = 0.013). The ratio of CRABP2 and FABP5 was related to ethnicity (p = 0.001), nerve invasion (p = 0.031), and postoperative treatment (p = 0.038). CRABP2 is positively associated with FABP5 (r = 0.156, p = 0.041) and the ratio (r = 0.334, p = 0.000), while there was a negative correlation between FABP5 and the ratio (r = −0.269, p = 0.000). Patients with CRABP2-positive expression had a significantly longer overall survival than patients with CRABP2-negative expression (p = 0.025). Conclusion CRABP2 as a suppressor factor is expected to be a potential prognosis marker for esophageal squamous cell carcinoma.

Download Full-text

A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: Role of ERCC1 expression.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e14502 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e14502-e14502

Author(s):

Jing Huang ◽

Yi Zhou ◽

Tao Qu ◽

Hong-Tu Zhang ◽

You-Sheng Mao ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Cancer ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Excision Repair ◽

Specific Marker ◽

Actuarial Survival ◽

Significant Difference ◽

Ercc1 Expression

e14502 Background: Recurrent or metastatic esophageal cancer has poor prognosis. Currently, the standard of care for esophageal cancer includes treatment with triweekly cisplatin-based chemotherapy. However, not all patients benefit from the treatment. To improve the response and identify specific marker for patient-personalized treatment, we designed this study to assess the efficacy and safety of biweekly paclitaxel and cisplatin combination for patients with recurrent or metastatic esophageal squamous cell carcinoma. The excision repair cross-complementation group 1 (ERCC1) expression to predict response is also assessed. Methods: Forty-six eligible patients were enrolled. Paclitaxel was given at 150 mg/m2 over 3 hours on day 1 and cisplatin was given at 50 mg/m2 on day 2, every 2 weeks as one cycle. ERCC1 protein expression was assessed by immunohistochemistry staining. Results: The overall response rate was 56.5% (26/46, 95% CI 42.2 %- 70.8%). Progression-free survival was 5.6 months (95% CI, 2.8-8.4 months) and the median actuarial survival time was 17.0 months (95% CI, 12.3-21.7months). There was a significant difference in median actuarial survival between the patients with a response compared to the non-responders (22.8 months vs. 7.4 months, p<0.0001). Overall survival at 1 year was 65.0%, and at 2 years was 34.0%, respectively. The most frequent toxicity for all patients was neutropenia (37.0% and 23.9% for grades 3 and 4, respectively). Patients with ERCC1 negative tumors had a higher treatment response than the ERCC1 positive group (radiological response rates; 92.3% vs.50%, p=0.013). Conclusions: Biweekly chemotherapy with paclitaxel and cisplatin was found to be active and generally well-tolerated. Our study indicates that expression of ERCC1 evaluated by immunohistochemistry is a promising predictive marker for response in patients with metastatic ESCC receiving cisplatin-paclitaxel regimen.

Download Full-text

The expression and prognostic value of SOX2, β-catenin and survivin in esophageal squamous cell carcinoma

Future Oncology ◽

10.2217/fon-2018-0884 ◽

2019 ◽

Vol 15 (36) ◽

pp. 4181-4195

Author(s):

Ya-Xing Zhou ◽

Qian Liu ◽

Hui Wang ◽

Fend Ding ◽

Yu-Qing Ma

Keyword(s):

Squamous Cell Carcinoma ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Clinicopathological Parameters ◽

Depth Of Invasion ◽

Node Metastasis ◽

Short Time

Aim: We mainly explored the effect of SOX2, β-catenin and survivin on prognosis in esophageal squamous cell carcinoma. Materials & methods: Immunohistochemistry was used to examine the expression of SOX2, β-catenin and survivin. χ2 test was used to analyze the relationship between proteins and clinicopathological parameters. Survival analysis was used to investigate the effect of three proteins on prognosis. Results: SOX2 was related to lymph node metastasis (p = 0.004) and vascular invasion (p = 0.041). β-catenin was associated with depth of invasion (p = 0.014), lymph node metastasis (p = 0.032) and postoperative chemoradiotherapy (p < 0.001). Survivin was related to gender (p = 0.022) and nerve invasion (p = 0.014). There was a positive correlation between SOX2 and β-catenin. Patients with SOX2 and β-catenin overexpression had poor prognosis. Survivin-positive patients who received postoperative chemoradiotherapy had a short time. Conclusion: SOX2, β-catenin and survivin can be used as prognostic markers of esophageal squamous cell carcinoma.

Download Full-text

Correlation of SOX4, SOX17, VE-cadherin and vasculogenic mimicry with the development and prognosis of esophageal squamous cell carcinoma

10.21203/rs.3.rs-166570/v1 ◽

2021 ◽

Author(s):

Yanzi Qin ◽

Wenjun Zhao ◽

Zhaogeng Cai ◽

Qi Wang ◽

Jin Gao ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Vasculogenic Mimicry ◽

Clinicopathological Parameters ◽

Depth Of Invasion ◽

Mrna Levels ◽

Mesenchymal Transition ◽

Node Metastasis

Abstract Background: We previously reported high SOX4 expression in esophageal squamous cell carcinoma (ESCC), which participates in the mechanism of vasculogenic mimicry (VM) by mediating the epithelial–mesenchymal transition (EMT) mechanism. In this study, the relationships between SOX4, SOX17, vascular endothelial (VE)-cadherin and VM were analyzed to explore the mechanisms of the occurrence and development of ESCC. Methods: SOX4, SOX17, and VE-cadherin expression as well as VM in 210 ESCC tissues and 60 normal esophageal mucosal tissues were determined by immunohistochemistry (IHC), and correlations with clinicopathological parameters were explored. The invasion, migration, and proliferation of EC9706 and Eca109 cells were determined after silencing of VE-cadherin with siRNA interference technology. SOX4, SOX17, and VE-cadherin protein and mRNA expression were quantified by Western blotting and qRT-PCR analyses, respectively.Results: Low SOX17 expression, high SOX4 expression, and high VE-cadherin expression were observed in ESCC tissues and were significantly correlated with tumor size, lymph node metastasis (LNM), depth of invasion, and pathological tumor node metastasis (pTNM) stage. They also were independent poor prognostic factors in ESCC patients. After VE-cadherin silencing, the invasion, migration, and proliferation of EC9706 and Eca109 cells in vitro were decreased, while SOX17 protein and mRNA levels were increased and SOX4 protein and mRNA levels were decreased.Conclusions: SOX17, SOX4, and VE-cadherin are involved in the development of ESCC. Low expression of SOX17 and high expression of SOX4 may promote VM in ESCC by enhancing VE-cadherin transcription.

Download Full-text

CDC20、TOP2A and NEK2 expression in esophageal squamous cell carcinoma and its clinical significance

Journal of Oncology Research ◽

10.30564/jor.v2i2.2549 ◽

2020 ◽

Vol 2 (2) ◽

Author(s):

Yanjiao Liu ◽

Longying He ◽

Qian Zhang ◽

Xinglong Zhang

Keyword(s):

Squamous Cell Carcinoma ◽

Survival Rate ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Normal Tissue ◽

Expression Level ◽

Cancer Tissue ◽

Adjacent Tissue ◽

Significant Difference

Objective: To study the expression of CDC20、TOP2A in esophageal squamous cell carcinoma and its relationship with survival of esophageal carcinoma.Methods :65 patients with esophageal squamous cell carcinoma from January 2016 to June 2018 were selected by computer random selection. All patients were treated with radical operation. The CDC20、TOP2A expression of the patients was examined. At the same time, the relationship between 3-year survival rate and CDC20、TOP2A was analyzed by follow-up investigation.Results: the CDC20、TOP2A expression level of cancer tissue group was higher than that of adjacent tissue group and normal tissue group (P <0.05), and the CDC20、TOP2A expression level of adjacent tissue group was higher than that of normal tissue group (P <0.05). There was no significant difference in sex, age, tumor size, tumor location and CDC20、TOP2A expression level in patients with esophageal squamous cell carcinoma, P >0.05; there were differences between groups (P P >0.05) and positive proportion in TNM stage, lymphatic metastasis, invasion factor and CDC20、TOP2A expression level; there were differences in tumor differentiation ,5-year survival rate and CDC20、TOP2A expression level (P P >0.05), and showed inverse proportion relationship.Conclusion: metastasis, recurrence and prognosis of esophageal squamous cell carcinoma are related to the level of CDC20、TOP2A expression. These two indexes can effectively evaluate the pathological situation of esophageal cancer and provide an important reference for the prognosis of esophageal squamous cell carcinoma patients.

Download Full-text

Divergent Metastatic Patterns Between Esophageal Squamous-cell Carcinoma and Esophageal Adenocarcinoma: a Propensity-matched Analysis

10.21203/rs.3.rs-499176/v1 ◽

2021 ◽

Author(s):

Ganwei Liu ◽

Feng Yang ◽

Shaodong Wang ◽

Jianfeng Li ◽

Zuli Zhou

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Cancer ◽

Brain Metastasis ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Esophageal Adenocarcinoma ◽

Squamous Cell ◽

Monitoring Strategies ◽

Significant Difference ◽

Metastatic Patterns

Abstract Background: To explore the different metastatic patterns between esophageal squamous-cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC).Methods: For this propensity-matched analysis, we used data from the latest iteration of the Surveillance, Epidemiology, and End Results (SEER) database and included patients diagnosed with esophageal cancer from 2010 to 2017. Results: A total of 20,189 patients were identified, including 6,610 ESCC and 13,579 EAC. After propensity score matching, 4597 pairs were selected. Compared with ESCC, EAC had a higher rate of liver metastasis (P < 0.001) and brain metastasis (P < 0.001), and a lower rate of lung metastasis (P < 0.001), with no signiﬁcant diﬀerence in bone metastasis (P = 0.255). The liver preferentially co-metastasized with lung in both cohorts. Brain metastasis was commonly observed in combination with other organ metastases in EAC. Conclusions: There are major differences in metastatic patterns between ESCC and EAC. The patterns identified may reflect the underlying biology of metastatic esophageal cancer and have potential to influence future monitoring strategies depending on clinical settings.

Download Full-text

Expression of CDC20、TOP2A in esophageal phosphorus carcinoma and its relationship with survival of esophageal carcinoma

Journal of Integrative Medicine ◽

10.30564/jim.v9i2.2555 ◽

2020 ◽

Vol 9 (2) ◽

Author(s):

Yanjiao Liu ◽

Longying He ◽

Qian Zhang ◽

Xinglong Zhang

Keyword(s):

Squamous Cell Carcinoma ◽

Survival Rate ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Normal Tissue ◽

Expression Level ◽

Cancer Tissue ◽

Adjacent Tissue ◽

Significant Difference

Download Full-text

HPV infection in Brazilian patients with esophageal squamous cell carcinoma: Interpopulational differences, lack of correlation with surrogate markers and clinicopathological parameters

Cancer Letters ◽

10.1016/j.canlet.2012.07.018 ◽

2012 ◽

Vol 326 (1) ◽

pp. 52-58 ◽

Cited By ~ 19

Author(s):

Suellen Herbster ◽

Cintia Tereza Lima Ferraro ◽

Natália Kirsch Koff ◽

Ana Rossini ◽

Cleber Dario Pinto Kruel ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Hpv Infection ◽

Clinicopathological Parameters ◽

Surrogate Markers ◽

Interpopulational Differences

Download Full-text

Racial Differences in Esophageal Squamous Cell Carcinoma: Incidence and Molecular Features

BioMed Research International ◽

10.1155/2017/1204082 ◽

2017 ◽

Vol 2017 ◽

pp. 1-9 ◽

Cited By ~ 2

Author(s):

Shirui Chen ◽

Kai Zhou ◽

Liguang Yang ◽

Guohui Ding ◽

Hong Li

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Cancer ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Racial Differences ◽

Squamous Cell ◽

Geographic Location ◽

Molecular Features ◽

Genome Wide ◽

White Patients

The incidence and histological type of esophageal cancer are highly variable depending on geographic location and race/ethnicity. Here we want to determine if racial difference exists in the molecular features of esophageal cancer. We firstly confirmed that the incidence rate of esophagus adenocarcinoma (EA) was higher in Whites than in Asians and Blacks, while the incidence of esophageal squamous cell carcinoma (ESCC) was highest in Asians. Then we compared the genome-wide somatic mutations, methylation, and gene expression to identify differential genes by race. The mutation frequencies of some genes in the same pathway showed opposite difference between Asian and White patients, but their functional effects to the pathway may be consistent. The global patterns of methylation and expression were similar, which reflected the common characteristics of ESCC tumors from different populations. A small number of genes had significant differences between Asians and Whites. More interesting, the racial differences of COL11A1 were consistent across multiple molecular levels, with higher mutation frequency, higher methylation, and lower expression in White patients. This indicated that COL11A1 might play important roles in ESCC, especially in White population. Additional studies are needed to further explore their functions in esophageal cancer.

Download Full-text